Key result
Connective tissue disease is linked to similar in-hospital mortality after TAVR compared to controls.
Why the study?
Data on the impact of connective tissue disease on transcatheter aortic valve replacement outcomes remain limited, necessitating a nationwide analysis.
Does transcatheter aortic valve replacement (TAVR) have comparable in-hospital outcomes in patients with connective tissue disease compared to those without?
Observational (n=90,298)
Yes
Does transcatheter aortic valve replacement (TAVR) have comparable in-hospital outcomes in patients with connective tissue disease compared to those without?
Answers are grounded in this paper and cite their sources.
TAVR appears to be a safe and feasible therapeutic option in patients with connective tissue disease, with in-hospital mortality and complication rates comparable to those without the disease.
PURPOSE: Given the systemic nature of connective tissue diseases (CTD), open surgical intervention for aortic stenosis is often considered high risk, making transcatheter aortic valve replacement (TAVR) a potentially preferable alternative. However, data on the impact of CTD on TAVR outcomes remain limited. Therefore, we conducted a nationwide analysis using the National Inpatient Sample (NIS) to examine trends and in-hospital outcomes of TAVR in patients with CTD in the United States. METHODS: A total of 90,298 patients undergoing TAVR between 2016 and 2022 were identified, representing over 451,000 weighted hospitalizations, including 3,821 (4.2%) with CTD. Multivariable regression was used to adjust for demographic, clinical, and hospital-level characteristics. CTD patients were more frequently female and had higher comorbidity indices, although many differences were small in absolute magnitude. RESULTS: In-hospital mortality was comparable between CTD and non-CTD groups (1.0% vs. 1.2%, p = 0.345). Rates of permanent pacemaker implantation and major complications, including vascular events, were similar. CTD patients demonstrated modestly shorter length of stay and lower inflation-adjusted hospitalization costs. Lower rates of cardiogenic shock, cardiac arrest, and mechanical ventilation were observed in the CTD cohort. In-hospital mortality declined significantly over time in the overall cohort, with a similar directional trend in CTD patients that did not reach statistical significance, likely due to smaller sample size. CONCLUSION: Overall, TAVR appears to be a safe and feasible therapeutic option in patients with CTD, with outcomes comparable to those without CTD.
No takes yet. Share an insight, caveat, or question.
Yasmin et al. (2026) conducted an observational in Aortic stenosis undergoing transcatheter aortic valve replacement (n=90,298). Connective tissue disease vs. No connective tissue disease was evaluated on In-hospital mortality (p=0.345). In patients undergoing transcatheter aortic valve replacement, the presence of connective tissue disease was associated with similar in-hospital mortality compared to those without the disease.
Synapse has enriched 10 related papers. Consider them for comparative context: